魔帝传奇隐藏:跪求英文翻译

求英文翻译
文章如下
The best news technologies of 2003

New technologies rarely change the world overnight, the tipping point is hard to predict. That’s why investing in tech startups is such a high-risk gamble. When does a technology become ‘real’?
When it’s first proven in the lab? When a prototype is unveiled at a press conference? When people line up to buy it?

The curve of progress is complicated by the fact that any given innovation, from conception to implementation, often evolves into something entirely different. Take the laser, for example: it grew out of an effort at bell laboratories to understand the molecular properties of gases. The scientists who invented it could never have imagined that, 50 years later, the laser would be a critical component in optical networking, surgical procedures, home stereos, and missile defense. As yogi Berra reportedly put it, the hardest thing to predict is the future.

This, more than anything, informed our approach to selecting the year’s most important new technologies. We looked for breakthroughs that, though perhaps not yet fully realized, have at least begun to make their presence felt in the marketplace. These aren’t the latest gadgets for playing mp3s or new-and-improved code to help you manage your payroll-they‘re broadly applicable innovations that's promise to change the way we work and live. And they’re not clear-cut, runaway successes-in fact, some have yet to make anyone a dime. But every one of them has big potential. And that’s what progress is all about.

1.Antiangiogenesis treatments
Fighting cancer by cutting off its food supply

The basic idea behind antiangiogenesis is simple: To stop a tumor, you must starve it to death. Yet like many simple ideas, this one has been difficult to achieve- until now.Antiangiogenic drugs work by halting the development of the blood vessels that cancerous cells need to grow .Unlike chemotherapy, however, antiangiogenesis is precisely targeted , so it doesn’t affect health cells - and thus antiangiogenesis treatments ,California -based Genentech this year announced that it’s Avastin drug therapy prolonged the lives of colon cancer patients. Avastin is now on track to secure FDA approval by early next year, and 60 other antiangiogenic drugs are in clinical trials, taking aim at diseases such as kidney cancer and melanoma. Says William Li, head of the nonprofits Angiogenesis Foundation ,”This could be as significant for cancer patients as penicillin was for infectious disease.”-SUSAN ORENSTEIN

Market size,2003: Not applicable
Market size,2009:＄ 10 billion (projected)
Companies to watch: Aeterna Laboratories, Celgene, Genentech, Novartis